Logo_AIHTA
  • Deutsch
  • Contact
    • Imprint
      • Privacy Notice
        • Newsletter
          • Sitemap
            Menu_button
            • News
              • About us
                • Research areas
                  • Research Projects
                    • Publications
                      • Search
                        • Synopsis of current research projects
                          • Synopsis of completed research projects
                            • HTA-Information Service Rapid Reviews
                              • Horizon Scanning in Oncology – Prioritisation of new and emerging oncologic drugs
                                • Horizon Scanning of Medicines - Reports and Fact Sheets
                                  • Horizon Scanning in Oncology – support for a budget-impact-calculation
                                    • Evaluation of individual medical procedures - Reports
                                      • All projects in an overview
                                        Video
                                        Video: What is HTA?    
                                        • Home
                                        • Research Projects
                                        • Horizon Scanning of Medicines - Reports and Fact Sheets

                                        Horizon Scanning of Medicines - Reports and Fact Sheets

                                        Bild1-long22

                                        Decision Support Documents

                                        Within the scope of the Horizon Scanning in Oncology project, the LBI-HTA periodically published assessments until 2019 on novel cancer drugs with a likely therapeutical and/or financial outcome. These assessments served as decision aids for funding agencies and the decision-making network "HTA in hospitals " alike.

                                        Since January 2020, monthly Fact Sheets will be conducted concerning all pharmaceutical (oncological) therapies that have received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency.

                                        Fact Sheets since January 2020:
                                         

                                        Fact Sheet No. 124 (February 2023)
                                        Cipaglucosidase alfa (Pombiliti®) in combination with Miglustat for the treatment of adults with late-onset Pompe disease (acid alpha-glucosidase [GAA] deficiency) New!

                                        Fact Sheet No. 123 (February 2023)
                                        Darolutamide (Nubeqa®) in combination with docetaxel and androgen deprivation therapy (ADT) for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC)

                                        Fact Sheet No. 122 (February 2023) Update
                                        Oportuzumab monatox (Vicineum®) for Bladder cancer

                                        Fact Sheet No. 121 (February 2023) Update
                                        Nadofaragen Firadenovec (Adstiladrin®) for Bladder cancer

                                        Fact Sheet No. 120 (February 2023)
                                        Trastuzumab deruxtecan (Enhertu®) for HER2-low breast cancer

                                        Fact Sheet No. 119 (February 2023)
                                        Tremelimumab (Tremelimumab AstraZeneca®) + Durvalumab (Imfinzi®) + Chemotherapy for NSCLC

                                        Fact Sheet No. 118 (February 2023)
                                        Tremelimumab (Imjudo®) + Durvalumab (Imfinzi®) for HCC

                                        Fact Sheet No. 117 (February 2023)
                                        Olaparib (Lynparza®) for mCRPC

                                        Fact Sheet No. 116 (December 2022) 
                                        Durvalumab (Imfinzi®) for Biliary tract cancer

                                        Fact Sheet No. 115 (December 2022) 
                                        Trastuzumab deruxtecan (Enhertu®) for Gastric or gastroesophageal junction (GEJ) adenocarcinoma

                                        Fact Sheet No. 114 (November 2022)
                                        Lutetium (177Lu) vipivotide tetraxetan (Pluvicto®) in combination with androgen deprivation therapy (ADT) with or without androgen receptor (AR) pathway inhibition for the treatment of metastatic castration-resistant prostate cancer (mCRPC)

                                        Fact Sheet No. 113 (November 2022) Update
                                        Cemiplimab (Libtayo®) as monotherapy for the treatment of recurrent or metastatic cervical cancer

                                        Fact Sheet No. 112 (November 2022) Update
                                        Zanubrutinib (Brukinsa®) as monotherapy for the treatment of adult patients with chronic lymphocytic leukaemia (CLL)

                                        Fact Sheet No. 111 (Oktober 2022) Update
                                        Axicabtagene ciloleucel (Yescarta®) for the treatment of patients with diffuse large B cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)

                                        Fact Sheet No. 110 (Oktober 2022) Update
                                        Zanubrutinib (Brukinsa®) as monotherapy for the treatment of marginal zone lymphoma (MZL)

                                        Fact Sheet No. 109 (Oktober 2022) Update
                                        Loncastuximab tesirine (Zynlonta®) as monotherapy for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)

                                        Fact Sheet No. 108 (August 2022) Update
                                        Selpercatinib (Retsevmo®) as monotherapy for the treatment of adults and adolescents 12 years and older with advanced RET mutant medullary thyroid cancer (MTC)

                                        Fact Sheet No. 107 (August 2022) Update
                                        Teclistamab (Tecvayli®) as monotherapy for the treatment of patients with relapsed and refractory multiple myeloma (MM) who have received at least three prior therapies

                                        Fact Sheet No. 106 (August 2022) Update
                                        Autologous anti-CD19-transduced CD3+ cells (Tecartus®) for the treatment of adult patients 26 years of age and above with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL)

                                        Fact Sheet No. 105 (August 2022) Update
                                        Relatlimab/nivolumab (Opdualag®) for the first line treatment of advanced melanoma in adults and adolescents 12 years of age and older with tumour cell PD-L1 expression < 1%

                                        Fact Sheet No. 104 (July 2022) Update
                                        Olaparib (Lynparza®) as monotherapy or in combination with endocrine therapy for the adjuvant treatment of patients with germline BRCA1/2-mutations who have HER2-negative, high risk early breast cancer

                                        Fact Sheet No. 103 (July 2022) Update
                                        Ibrutinib (Imbruvica®) in combination with venetoclax for the treatment of previously untreated chronic lymphocytic leukaemia (CLL)

                                        Fact Sheet No. 102 (July 2022) Update
                                        Trastuzumab deruxtecan (Enhertu®) as monotherapy for the treatment of unresectable or metastatic HER2 positive breast cancer

                                        Fact Sheet No. 101 (July 2022) Update
                                        Asciminib (Scemblix®) for the treatment of Philadelphia chromosome?positive (Ph+) chronic myeloid leukaemia (CML) in chronic phase (CP)

                                        Fact Sheet No. 100 (July 2022) Update
                                        Melphalan flufenamide (Pepaxti®) with dexamethasone for the treatment of multiple myeloma (MM)

                                        Fact Sheet No. 99 (June 2022) Update
                                        Pembrolizumab (Keytruda) as monotherapy for the adjuvant treatment of stage IIb IIc III melanoma

                                        Fact Sheet No. 98 (June 2022) Update
                                        Selinexor (Nexpovio®) in and dexamethasone for the treatment of multiple myeloma (MM)

                                        Fact Sheet No. 97 (May 2022) Update
                                        Axicabtagene ciloleucel (Yescarta®) Follicular lymphoma

                                        Fact Sheet No. 96 (May 2022) Update
                                        Atezolizumab (Tecentriq®) NSCLC

                                        Fact Sheet No. 95 (May 2022) Update
                                        Selpercatinib (Retsevmo®) NSCLC

                                        Fact Sheet No. 94  (May 2022) Update
                                        Pembrolizumab (Keytruda®) TNBC

                                        Fact Sheet No. 93 (May 2022) Update
                                        Capmatinib (Tabrecta®) NSCLC 

                                        Fact Sheet No. 92 (May 2022) Update
                                        Mosunetuzumab (Lunsumio®) Follicular lymphoma

                                        Fact Sheet No. 91 (April 2022) Update
                                        Pembrolizumab (Keytruda®) in combination with chemotherapy with or without bevacizumab for cervical cancer

                                        Fact Sheet No. 90 (April 2022) Update
                                        Pembrolizumab (Keytruda®) as monotherapy in adults with colorectal cancer

                                        Fact Sheet No. 89 (April 2022) Update
                                        Polatuzumab vedotin (Polivy®) in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for the treatment of B-cell lymphoma (DLBCL)

                                        Fact Sheet No. 88 (April 2022) Update
                                        Tisagenlecleucel (Kymriah®) for the treatment of follicular lymphoma (FL) after two or more lines of systemic therapy

                                        Fact Sheet No. 87 (April 2022) Update
                                        Cabozantinib (Cabometyx®) as monotherapy for the treatment of thyroid carcinoma (DTC)

                                        Fact Sheet No. 86 (April 2022) Update
                                        Ciltacabtagene autoleucel (Carvykti®) for the treatment of multiple myeloma (MM)

                                        Fact Sheet No. 85 (März 2022) 2. Update
                                        Enfortumab vedotin (Padcev®) as monotherapy for the treatment of patients with locally advanced or metastatic urothelial cancer

                                        Fact Sheet No. 84 (März 2022) Update 
                                        Abemaciclib (Verzenios®) bei early breast cancer

                                        Fact Sheet No. 83 (März 2022) Update
                                        Nivolumab (Opdivo®) + chemotherapy bei OSCC

                                        Fact Sheet No. 82 (März 2022) Update
                                        Ipilimumab (Yervoy®) + Nivolumab (Opdivo®) bei OSCC

                                        Fact Sheet No. 81 (März 2022) Update
                                        Nivolumab (Opdivo®) bei MIUC

                                        Fact Sheet No. 80 (März 2022) 2. Update
                                        Relugolix (Orgovyx®) bei Prostate Cancer

                                        Fact Sheet No. 79 (März 2022) 2. Update
                                        Tebentafusp (Kimmtrak®) bei Uveal melanoma

                                        Fact Sheet No. 78 (February 2022) Update
                                        Avapritinib (Ayvakyt®) for the treatment of advanced systemic mastocytosis (AdvSM)

                                        Fact Sheet No. 77 (February 2022) Update
                                        Lisocabtagene maraleucel (Breyanzi) for the treatment of relapsed or refractory DLBCL

                                        Fact Sheet No. 76 (January 2022) Update
                                        Tegafur/gimeracil/oteracil (Teysuno®) for the treatment of metastatic colorectal cancer

                                        Fact Sheet No. 75 (January 2022) Update
                                        Lorlatinib (Lorviqua®) as monotherapy for the treatment of anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC)

                                        Fact Sheet No. 74 (January 2022) Update
                                        Pembrolizumab (Keytruda®) as monotherapy for the adjuvant treatment of renal cell carcinoma (RCC)

                                        Fact Sheet No. 73 (January 2022) Update
                                        Tepotinib (Tepmetko®) as monotherapy for the treatment of patients with advanced non-small cell lung cancer (NSCLC)

                                        Fact Sheet No. 72 (January 2022) 
                                        Enfortumab vedotin (Padcev®) as monotherapy for the treatment of patients with locally advanced or metastatic urothelial cancer

                                        Fact Sheet No. 71 (November 2021) Update
                                        Sotorasib (Lumykras®): Sotorasib (Lumykras®) as monotherapy for the treatment of advanced NSCLC with KRAS G12C mutation

                                        Fact Sheet No. 70 (November 2021) Update
                                        Sacituzumab govitecan (Trodelvy) as monotherapy for the treatment of patients with unresectable or metastatic triple-negative breast cancer (mTNBC)  

                                        Fact Sheet No. 69 (November 2021) Update
                                        Amivantamab (Rybrevant) as monotherapy for the treatment of patients with advanced non-small cell lung cancer (NSCLC)

                                        Fact Sheet No. 68 (November 2021) Update
                                        Pembrolizumab (Keytruda) in combination with Lenvatinib (Kisplyx) for the treatment of advanced or recurrent endometrial carcinoma (EC)

                                        Fact Sheet No. 67 (November 2021) Update
                                        Pembrolizumab (Keytruda) in combination with Lenvatinib (Kisplyx) for the firstline treatment of advanced renal cell carcinoma (RCC)

                                        Fact Sheet No. 66 (July 2022) 
                                        Degarelix (Firmagon®) as a neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone-dependent prostate cancer

                                        Fact Sheet No. 65 (July 2022) 
                                        Degarelix (Firmagon®) as a neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone-dependent prostate cancer 

                                        Fact Sheet No. 64 (October 2021) Update
                                        Pembrolizumab (Keytruda®) in combination with chemotherapy for the treatment of locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC)

                                        Fact Sheet No. 63 (October 2021) Update
                                        Nivolumab (Opdivo®) in combination with fluoropyrimidine- and platinum-based combination chemotherapy for the treatment of patients with HER2?negative advanced or metastatic gastric, gastro?oesophageal junction or oesophageal adenocarcinoma

                                        Fact Sheet No. 62 (October 2021) 2. Update
                                        Ripretinib (Qinlock®) for the treatment of patients with advanced gastrointestinal stromal tumour (GIST)

                                        Fact Sheet No. 61 (October 2021) 2. Update
                                        Pralsetinib (Gavreto®) as monotherapy for the treatment of patients with rearranged during transfection (RET) fusion-positive advanced non-small cell lung cancer (NSCLC)

                                        Fact Sheet No. 60 (October 2021) Update
                                        Zanubrutinib (Brukinsa®) as monotherapy for the treatment of patients with waldenström’s macroglobulinaemia (WM)

                                        Fact Sheet No. 59 (July 2021) Update
                                        Adjuvant nivolumab (Opdivo®) as monotherapy for the treatment of patients with oesophageal (OC) or gastro-oesophageal junction cancer (GEJC)

                                        Fact Sheet No. 58 (July 2021) Update
                                        Tafasitamab (Minjuvi®; Monjuvi®) for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

                                        Fact Sheet No. 57 (July 2021) Update
                                        Idecabtagene vicleucel (Abecma®) for the treatment of patients with relapsed and refractory multiple myeloma (MM)

                                        Fact Sheet No. 56 (May 2021) Update
                                        Daratumumab (Darzalex®) in combination with cyclophosphamide, bortezomib and dexamethasone for the treatment of newly diagnosed systemic light chain (AL) amyloidosis

                                        Fact Sheet No. 55 (May 2021) Update
                                        Daratumumab (Darzalex®) in combination with pomalidomide and dexamethasone for the treatment of multiple myeloma (MM)

                                        Fact Sheet No. 54 (May 2021) Update
                                        Pembrolizumab (Keytruda®) in combination with platinum and fluoropyrimidine based chemotherapyfor the treatment of locally advanced unresectable or metastatic carcinoma of the oesophagus

                                        Fact Sheet No. 53 (May 2021) Update
                                        Cemiplimab (Libtayo®) as monotherapy for the treatment of locally advanced or metastatic basal cell carcinoma (laBCC or mBCC)

                                        Fact Sheet No. 52 (May 2021) Update
                                        Cemiplimab (Libtayo®) as monotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC)

                                        Fact Sheet No. 51 (May 2021) Update
                                        Nivolumab (Opdivo®) in combination with ipilimumab (Yervoy®) for the treatment of patients with mismatch repair deficient (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer

                                        Fact Sheet No. 50 (April 2021) Update
                                        Nivolumab (Opdivo®) in combination with ipilimumab for the first-line treatment of patients with unresectable malignant pleural mesothelioma

                                        Fact Sheet No. 49 (April 2021) Update
                                        Venetoclax (Venclyxto®) in combination with a hypomethylating agent for the treatment of patients with newly diagnosed acute myeloid leukaemia (AML)

                                        Fact Sheet No. 48 (April 2021) Update
                                        Osimertinib (Tagrisso®) as monotherapy for the adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA non-small cell lung cancer (NSCLC)

                                        Fact Sheet No. 47 (April 2021) Update
                                        Azacitidine (Onureg®) for the maintenance treatment of patients with acute myeloid leukaemia (AML)

                                        Fact Sheet No. 46 (March 2021) Update
                                        Enzalutamide (Xtandi®) for the treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT)

                                        Fact Sheet No. 45 (March 2021) Update
                                        Atezolizumab (Tecentriq®) as monotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC)

                                        Fact Sheet No. 44 (March 2021) Update
                                        Duvelisib (Copiktra®) for the treatment of patients with relapsed or refractory chronic lymphocytic leukaemia (CLL) and refractory follicular lymphoma (FL)

                                        Fact Sheet No. 43 (February 2021) Update
                                        Isatuximab (Sarclisa®) in combination with carfilzomib and dexamethasone for the treatment of patients with multiple myeloma (MM)

                                        Fact Sheet No. 42 (February 2021) Update
                                        Nivolumab (Opdivo®) in combination with cabozantinib (Cabometyx®) for the first-line treatment of patients with advanced renal cell carcinoma (RCC)

                                        Fact Sheet No. 41 (February 2021) 2. Update 
                                        Dostarlimab (Jemperli®) for the treatment of patients with recurrent or advanced mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) endometrial cancer (EC)

                                        Fact Sheet No. 40 (January 2021) Update
                                        Pemigatinib (Pemazyre®) for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement

                                        Fact Sheet No. 39 (January 2021) 2. Update
                                        Selinexor (Nexpovio®) in combination with dexamethasone for the treatment of relapsed and refractory multiple myeloma (MM)

                                        Fact Sheet No. 38 (January 2021) Update
                                        Pembrolizumab (Keytruda®) is indicated for the treatment of adult and paediatric patients with relapsed or refractory classical Hodgkin lymphoma (cHL)

                                        Fact Sheet No. 37 (Dezember 2020) Update
                                        Tucatinib (Tukysa®) with trastuzumab and capecitabine for the treatment of HER2-positive locally advanced or metastatic breast cancer

                                        Fact Sheet No. 36 (Dezember 2020) Update
                                        Selpercatinib (Retsevmo®) for the treatment of RET-fusion positive NSCLC, RET-fusion positive thyroid cancer and RET-mutant medullary-thyroid cancer

                                        Fact Sheet No. 35 (Dezember 2020) 2. Update
                                        Moxetumomab pasudotox (Lumoxiti®) for the treatment of patients with relapsed or refractory hairy cell leukaemia (HCL)

                                        Fact Sheet No. 34 (Dezember 2020) Update
                                        Pembrolizumab (Keytruda®) as monotherapy for the first-line treatment of MSI H or dMMR colorectal cancer

                                        Fact Sheet Nr. 33 (Dezember 2020) 2. Update
                                        Fedratinib (Inrebic®) for the treatment of primary and secondary myelofibrosis

                                        Fact Sheet No. 32 (Dezember 2020) Update
                                        Trastuzumab deruxtecan (Enhertu®) in patients with previously treated HER2-positive breast cancer

                                        Fact Sheet No. 31 (Dezember 2020) Update
                                        Avelumab (Bavencio®) as monotherapy for the first-line maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma

                                        Fact Sheet No. 30 (November 2020) Update
                                        A fixed-dose combination of pertuzumab, trastuzumab and hyaluronidase-zzxf (PhesgoTM) for the treatment of early and metastatic breast cancer

                                        Fact Sheet No. 29 (November 2020) Update
                                        Carfilzomib (Kyprolis®) with daratumumab and dexamethasone for the treatment of adult patients with multiple myeloma (MM)

                                        Fact Sheet No. 28 (November 2020) 2. Update
                                        Tagraxofusp (Elzonris®) in blastic plasmacytoid dendritic-cell neoplasm (BPDCN)

                                        Fact Sheet No. 27 (October 2020) Update
                                        Autologous anti-CD19-transduced CD3+ cells (Tecartus®) for the treatment of relapsed or refractory mantle cell lymphoma (MCL)

                                        Fact Sheet No. 26 (October 2020) Update
                                        Nivolumab (Opdivo®) as monotherapy for the treatment of unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma (OESCC)

                                        Fact Sheet No. 25 (October 2020) Update
                                        Blinatumomab (Blincyto®) for the treatment of patients with Philadelphia chromosome positive B-precursor acute lymphoblastic leukaemia (ALL)

                                        Fact Sheet No. 24 (September 2020) Update
                                        Olaparib (Lynparza®) plus bevacizumab as first-line maintenance treatment in patients with ovarian cancer

                                        Fact Sheet No. 23 (September 2020) Update
                                        Olaparib (Lynparza®) for metastatic castration-resistant prostate cancer (mCRPC)  

                                        Fact Sheet No. 22 (September 2020) Update
                                        Niraparib (Zejula®) in patients with newly diagnosed advanced ovarian cancer

                                        Fact Sheet No. 21 (September 2020) Update
                                        Nivolumab (Opdivo®) plus ipilimumab (Yervoy®) and chemotherapy as first-line treatment for metastatic non-small cell lung cancer (NSCLC)

                                        Fact Sheet No. 20 (September 2020) Update
                                        Atezolizumab (Tecentriq®) plus bevacizumab for the treatment of advanced or unresectable hepatocellular carcinoma (HCC)

                                        Fact Sheet No. 19 (Juli 2020) Update
                                        Ibrutinib (Imbruvica®) as a single agent or in combination with rituximab or obinutuzumab  for the treatment of previously untreated chronic lymphocytic leukaemia (CLL)

                                        Fact Sheet No. 18 (Juli 2020) Update
                                        Durvalumab (Imfinzi®) in combination with etoposide and either carboplatin or cisplatin for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC)

                                        Fact Sheet No. 17 (Juli 2020) Update
                                        Belantamab mafodotin (Blenrep®) as monotherapy for the treatment of relapsed or refractory multiple myeloma (MM)

                                        Fact Sheet No. 16 (Juli 2020) 2. Update
                                        Avapritinib (Ayvakyt®) for the treatment of gastrointestinal stromal tumours (GIST)

                                        Fact Sheet No. 15 (Juli 2020) Update
                                        Acalabrutinib (Calquence®) for the treatment of chronic lymphocytic leukaemia (CLL)

                                        Fact Sheet No. 14 (ad April 2020)
                                        Carmustine (Carmustine Obvius®) as conditioning treatment before transplantation in patients with Hodgkin’s lymphoma (HL) and non-Hodgkin’s lymphomas (NHL) 

                                        Fact Sheet No. 13 (Mai 2020) Update
                                        Entrectinib (Rozlytrek®) for the treatment of patients whose solid tumours have a NTRK gene fusion, or patients with ROS1-positive advanced NSCLC

                                        Fact Sheet No. 12 (Mai 2020) Update 
                                        Alpelisib (Piqray®) plus fulvestrant for PIK3CA-mutated, hormone receptor–positive advanced breast cancer

                                        Fact Sheet No. 11 (Mai 2020) 
                                        Maintenance olaparib (Lynparza®) for the treatment of patients with germline BRCA-mutated metastatic pancreatic cancer

                                        Fact Sheet No. 10 (April 2020)
                                        Glasdegib (Daurismo®) with low-dose cytarabine (LDAC) in patients with newly diagnosed acute myeloid leukaemia (AML)

                                        Fact Sheet No. 9 (April 2020) 
                                        Daratumumab (Darzalex®) in a new pharmaceutical form associated with a new strength and a new route of administration for the treatment of multiple myeloma

                                        Fact Sheet No. 8 (April 2020) Update
                                        Cabazitaxel Accord for the treatment of patients with metastatic castration resistant prostate cancer (mCRPC) previously treated with a docetaxel containing regimen

                                        Fact Sheet No. 7 (April 2020) 
                                        Encorafenib (Braftovi®) in combination with cetuximab for the treatment of adult patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation

                                        Fact Sheet No. 6 (March 2020) 
                                        Isatuximab (Sarclisa®) plus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (MM)

                                        Fact Sheet No. 5 (March 2020) 
                                        Brentuximab vedotin (Adcetris®) with chemotherapy for CD30-positive peripheral T-cell lymphoma (PTCL)

                                        Fact Sheet No. 4 (February 2020) 
                                        Brigatinib (Alunbrig®) in ALK-positive non–small-cell lung cancer (NSCLC)

                                        Fact Sheet No. 3 (January 2020)
                                        Rituximab (MabThera®) for the treatment of paediatric patients with previously untreated advanced stage CD20 positive DLBCL, BL, BAL, or BLL

                                        Fact Sheet No. 2 (January 2020) 
                                        Darolutamide (Nubeqa®) in nonmetastatic, castration-resistant prostate cancer (nmCRPC)

                                        Fact Sheet No. 1 (January 2020) 
                                        Venetoclax (Venclyxto®) and obinutuzumab in patients with chronic lymphocytic leukaemia (CLL) and coexisting conditions

                                         

                                        Publikation series October 2009 - December 2020 (in English):

                                        DSD HSO No 91
                                        Pembrolizumab (Keytruda®) as first-line therapy for PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (NSCLC)

                                        DSD HSO No. 90
                                        Enzalutamide (Xtandi®) in addition to standard first-line therapy in men with metastatic hormone-sensitive prostate cancer (mHSPC)

                                        DSD HSO No. 89
                                        Brentuximab vedotin (Adcetris®) in combination with chemotherapy for CD30-positive peripheral T-cell lymphoma (PTCLs)

                                        DSD HSO No. 88
                                        Darolutamide for the treatment of patients with nonmetastatic castration-resistant prostate cancer (CRPC)

                                        DSD HSO No. 87
                                        Atezolizumab (Tecentriq®) with nab-paclitaxel (Abraxane®) for the treatment of advanced triple-negative breast cancer (aTNBC)

                                        DSD HSO No. 86
                                        Olaparib (Lynparza®) as first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer'

                                        DSD HSO No. 85
                                        Ibrutinib (Imbruvica®) in combination with rituximab for the treatment of Waldenström’s macroglobulinemia

                                        DSD HSO No. 84
                                        Enzalutamide (Xtandi®) in patients with nonmetastatic, castration-resistant prostate cancer (CRPC)

                                        DSD HSO No. 83
                                        Pembrolizumab (Keytruda®) in combination with chemotherapy for the treatment of metastatic non-small-cell lung cancer (NSCLC)

                                        DSD HSO No. 82
                                        Nivolumab (Opdivo®) in combination with ipilimumab (Yervoy®) for the first-line treatment of patients with advanced RCC

                                        DSD HSO No. 81
                                        Daratumumab (Darzalex®) in combination with bortezomib, melphalan and prednisone for untreated myeloma

                                        DSD HSO No. 80
                                        Osimertinib (Tagrisso®) for the initial treatment of EGFR-mutated advanced non–small-cell lung cancer (NSCLC)

                                        DSD HSO No. 79
                                        Rituximab (MabThera®) after autologous stem-cell transplantation (ASCT) in mantle cell lymphoma (MCL)

                                        DSD HSO No. 78
                                        Abemaciclib (Verzenio®) in combination with a nonsteroidal aromatase inhibitor (NSAI) as initial therapy for advanced breast cancer (ABC)

                                        DSD HSO No. 77
                                        Alectinib as monotherapy for the first-line treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC)

                                        DSD HSO No. 76
                                        Durvalumab (Imfinzi™) for the treatment of patients with stage III non-small-cell lung cancer after prior chemoradiotherapy

                                        DSD HSO No. 75
                                        Nivolumab (Opdivo®) for metastatic DNA mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal cancer (CRC)

                                        DSD HSO No. 74
                                        Midostaurin with standard chemotherapy in FLT3-Positive Acute Myeloid Leukaemia 

                                        DSD HSO No. 73
                                        Regorafenib indicated  as monotherapy for the treatment of adult patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib  

                                        DSD HSO No. 72
                                        Abemaciclib (Verzenio®) in combination with fulvestrant for treatment of HR-positive, HER2-negative advanced breast cancer (ABC) 

                                        DSD HSO No. 71
                                        Olaparib (Lynparza®) in patients with BRCA-mutated metastatic breast cancer 

                                        DSD HSO No. 70
                                        Pembrolizumab (Keytruda®) as second-line treatment for patients with advanced urothelial carcinoma (UC)

                                        DSD HSO No. 69
                                        Ceritinib (Zykadia®) as first-line therapy for patients with advanced ALK-positive non-small cell lung cancer

                                        DSD HSO No. 68
                                        Atezolizumab (Tecentriq®) in previously treated non-small cell lung cancer (NSCLC)

                                        DSD HSO No. 67
                                        Ipilimumab (Yervoy®) in the adjuvant therapy for high-risk stage III cutaneous melanoma

                                        DSD HSO No. 66
                                        Neratinib for the treatment of patients with HER2-positive breast cancer after trastuzumab-based adjuvant therapy

                                        DSD HSO No. 65
                                        Ribociclib in combination with letrozole for the first-line therapy of HR-positive, HER2-negative recurrent or metastatic breast cancer

                                        DSD HSO No. 64
                                        Palbociclib (Ibrance®) in combination with fulvestrant for the treatment of hormone-receptor-positive, HER2-negative advanced or metastatic breast cancer

                                        DSD HSO No. 63
                                        Ixazomib (Ninlaro®) in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma (MM)

                                        DSD HSO No. 62
                                        Venetoclax (VenclextaTM) for the treatment of relapsed or refractory chronic lymphocytic leukaemia (CLL) with chromosome 17p deletion

                                        DSD HSO No. 61
                                        Atezolizumab (TecentriqTM) for the treatment of locally advanced and metastatic urothelial carcinoma 

                                        DSD HSO No. 60
                                        Obinutuzumab (Gazyvaro®) in combination with bendamustine for the treatment of relapsed/refractory follicular lymphoma (FL)

                                        DSD HSO No. 59
                                        Afatinib (Giotrif®) in patients with non-small cell lung cancer (NSCLC) who are refractory to erlotinib/gefitinib and afatinib monotherapy

                                        DSD HSO No. 58
                                        Pembrolizumab (Keytruda®) in previously treated advanced non-small cell lung cancer (NSCLC)

                                        DSD HSO No. 57
                                        Ofatumumab (Arzerra®) as maintenance therapy in patients with relapsed chronic lymphocytic leukaemia (CLL)

                                        DSD HSO No. 56
                                        Bevacizumab (Avastin®) in addition to standard chemotherapy for the first-line treatment of ovarian cancer

                                        DSD HSO No. 55
                                        Pembrolizumab (Keytruda®) for the treatment of advanced melanoma

                                        DSD HSO No. 54
                                        Ramucirumab in combination with paclitaxel as second-line treatment for adult patients with advanced gastric or gastro-oesophageal junction carcinoma

                                        DSD HSO No. 53
                                        Nivolumab (Nivolumab BMS®) for the second-line therapy of metastatic squamous non-small cell lung cancer

                                        DSD HSO No. 52
                                        Carfilzomib (Kyprolis®) for patients with relapsed multiple myeloma who have received one to three prior lines of therapy

                                        DSD HSO No. 51
                                        Bevacizumab (Avastin®) in combination with chemotherapy as second-line therapy for HER2-negative, locally recurrent or metastatic breast cancer that has progressed after first-line treatment with bevacizumab plus chemotherapy

                                        DSD HSO No. 50
                                        Nivolumab (Opdivo®) as single-agent first-line therapy for unresectable or metastatic melanoma

                                        DSD HSO No. 49
                                        Idelalisib (Zydelig®) in addition to rituximab for the treatment of relapsed chronic lymphocytic leukaemia

                                        DSD HSO No. 48
                                        Bevacizumab (Avastin®) for platinum-resistant recurrent, epithelial ovarian, fallopian tube or primary peritoneal cancer

                                        DSD HSO No. 47
                                        Ibrutinib (Imbruvica®) for relapsed or refractory chronic lymphocytic leukaemia

                                        DSD HSO No. 46
                                        Bevacizumab (Avastin®) as maintenance therapy after first progression on bevacizumab for patients with advanced colorectal carcinoma

                                        DSD HSO No. 45
                                        Obinutuzumab (Gazyva®) for previously untreated patients with chronic lymphocytic leukaemia (CLL)

                                        DSD HSO No. 44
                                        Radium-223 dichloride (Xofigo®) for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease

                                        DSD HSO No. 43
                                        Nab-Paclitaxel (Abraxane®) as first-line therapy for metastatic adenocarcinoma of the pancreas

                                        DSD HSO No. 42
                                        Dabrafenib (Tafinlar®) in previously untreated subjects with BRAF mutation-positive advanced (stage III) or metastatic (stage IV) melanoma

                                        DSD HSO No. 41
                                        Afatinib (Giotrif®) for the treatment of EGFR TKI-naïve adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s)

                                        DSD HSO No. 40
                                        Regorafenib (Stivarga®) for heavily pretreated patients with metastatic colorectal cancer (mCRC)

                                        DSD HSO No. 39
                                        Pomalidomide (Pomalyst®) for the ? 3rd-line therapy of patients with relapsed and refractory multiple myeloma

                                        DSD HSO No. 38
                                        Aflibercept (Zaltrap®) in addition to FOLFIRI for the 2nd line therapy of metastatic colorectal cancer

                                        DSD HSO No. 37
                                        Enzalutamide (Xtandi®) for patients with progressive castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy

                                        DSD HSO No. 36
                                        Trastuzumab emtansine (KadcylaTM) for previously treated patients with
                                        HER2-positive advanced/ metastatic breast cancer

                                        DSD HSO No. 35
                                        Crizotinib (Xalkori®) for the treatment of anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC)

                                        DSD HSO No. 34
                                        Trametinib for advanced or metastatic BRAF V600 mutation-positive melanoma

                                        DSD HSO No. 33
                                        Lenalidomide (Revlimid®) for the first-line therapy of transplant-ineligible patients with multiple myeloma

                                        DSD HSO No. 32
                                        Everolimus (Afinitor® or Votubia®) in combination with exemestane in postmenopausal women with oestrogen receptor positive, HER2-negative locally advanced or metastatic breast cancer who are refractory to letrozole or anastrozole

                                        DSD HSO No. 31
                                        Pertuzumab (Omnitarg/Perjeta®) for the first-line therapy of metastatic HER2 positive breast cancer

                                        DSD HSO No. 30
                                        Ipilimumab (Yervoy®) for the first-line therapy of advanced/metastatic cutaneous melanoma

                                        DSD HSO No. 29
                                        Bortezomib (Velcade®) as consolidation or maintenance therapy after autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma

                                        DSD HSO No. 28
                                        Lenalidomide (Revlimid®) for the treatment of low /intermediate-1 risk myelodysplastic syndrome with chromosome 5q deletion

                                        DSD HSO No. 27
                                        Bevacizumab (Avastin®) in combination with chemotherapy in previously treated metastatic breast cancer

                                        DSD HSO No. 26
                                        Brentuximab (Adcetris®) for the treatment of relapsed Hodgkin’s lymphoma (HL) or relapsed systemic anaplastic large cell lymphoma (sALCL)

                                        DSD HSO No. 25
                                        Romidepsin (Istodax®) for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) after prior systemic therapy  

                                        DSD HSO No. 24
                                        Everolimus (Afinitor®) for the treatment of unresectable or metastatic neuroendocrine tumours of pancreatic origin

                                        DSD HSO No. 23
                                        Vemurafenib for patients with BRAF V600E mutation positive advanced/metastatic melanoma

                                        DSD HSO No. 22
                                        Erlotinib (Tarceva®) for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer with EGFR activating mutations

                                        DSD HSO No. 21
                                        Axitinib (AG013736, Inlyta®) for the second-line treatment of metastatic renal cell carcinoma (mRCC)

                                        DSD HSO No. 20
                                        Abiraterone acetate (ZytigaTM) as 2nd-line therapy for the treatment of metastatic castration-resistant prostate cancer after docetaxel therapy

                                        DSD HSO No. 19
                                        S-1 (TeysunoTM) as first-line therapy for patients with advanced non-small cell lung cancer

                                        DSD HSO No. 18
                                        Eribulin (Halaven®) as third- or late- line mono-therapy for advanced/metastatic breast cancer

                                        DSD HSO No. 17
                                        Dasatinib (Sprycel®) for the 1st-line treatment of Philadelphia-chromosome positive chronic myeloid leukemia in the chronic phase

                                        DSD HSO No. 16
                                        Second-line chemotherapy with cabazitaxel (Jevtana®) for the treatment of castration-resistant metastatic prostate cancer

                                        DSD HSO No. 15
                                        Nilotinib (Tasigna®) for the 1st-line treatment of Philadelphia chromosome positive chronic myeloid leukemia in the chronic phase

                                        DSD HSO No. 14
                                        Ipilimumab for pre-treated patients with advanced/metastatic melanoma

                                        DSD HSO No. 13
                                        Pazopanib (Votrient®) for the treatment of locally advanced and/or metastatic renal cell carcinoma

                                        DSD HSO No. 12
                                        Trastuzumab (Herceptin®) in addition to standard chemotherapy as first-line therapy for advanced gastric cancer

                                        DSD HSO No. 11
                                        Panitumumab (Vectibix®) for the first-line treatment of metastatic colorectal cancer

                                        DSD HSO No. 11/ 1st update 2011
                                        Panitumumab (Vectibix®) as 1st-line combination therapy for the treatment of WT KRAS metastatic colorectal cancer

                                        DSD HSO No. 10
                                        Bendamustine (Ribomustin®/Treanda®/ Levact®) for indolent non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukaemia (CLL) and multiple myeloma

                                        DSD HSO No. 9
                                        Lapatinib ditosylate (Tyverb/Tykerb®) as first-line therapy for the treatment of advanced/metastatic breast cancer

                                        DSD HSO No. 8
                                        Plerixafor (Mozobil®) for autologous stem cell transplantation in patients with lymphoma and multiple myeloma

                                        DSD HSO No. 7
                                        Trabectedin (Yondelis®) for second-line recurrent platinum-sensitive ovarian cancer

                                        DSD HSO No. 6
                                        Gefitinib (Iressa®) for the first-line treatment of non-small cell lung cancer

                                        DSD HSO No. 6/ 1st update 2011
                                        Gefitinib (Iressa®) for the 1st-line treatment of non-small cell lung cancer – 1st Update 2011

                                        DSD HSO No. 5
                                        Ibritumomab tiuxetan (Zevalin®) as consolidation therapy after first remission in patients with follicular lymphoma

                                        DSD HSO No. 4
                                        Rituximab (Rituxan®/MabThera®) for the first- and second-line treatment of chronic lymphocytic leukaemia

                                        DSD HSO No.4/ 1st update 2011
                                        Rituximab (Rituxan®/MabThera®) for the first- and second-line treatment of chronic lymphocytic leukaemia – 1st Update 2011

                                        DSD HSO No. 3
                                        Everolimus (Afinitor®) for the treatment of advanced/metastatic kidney cancer

                                        DSD HSO No. 2
                                        Cetuximab (Erbitux®) in EGFR-expressing Non-Small Cell Lung Cancer

                                        DSD HSO No. 1
                                        Azacitidine (Vidaza®) for the treatment of myelodysplastic syndromes

                                        Contact: Nicole Grössmann

                                        • News
                                          • Announcements
                                            • Events
                                              • Newsletter
                                                • Press release on our reports
                                                  • Press photos
                                                  • About us
                                                    • Evaluation
                                                      • History
                                                        • Methods
                                                          • Team
                                                            • Shareholder & organization chart
                                                              • Stakeholder involvement
                                                                • Press clippings
                                                                • Research areas
                                                                  • Oncology
                                                                    • High tech medicine
                                                                      • Rehabilitation and occupational therapy
                                                                        • Prevention and screening
                                                                          • Psychological & psychiatric interventions
                                                                            • Health economics
                                                                              • European collaboration
                                                                                • HTA-methods & steering instruments
                                                                                  • Complementary medicine
                                                                                  • Research Projects
                                                                                    • Synopsis of current research projects
                                                                                      • Synopsis of completed research projects
                                                                                        • HTA-Information Service Rapid Reviews
                                                                                          • Horizon Scanning in Oncology – Prioritisation of new and emerging oncologic drugs
                                                                                            • Horizon Scanning of Medicines - Reports and Fact Sheets
                                                                                              • Horizon Scanning in Oncology – support for a budget-impact-calculation
                                                                                                • Evaluation of individual medical procedures - Reports
                                                                                                  • All projects in an overview
                                                                                                  • Publications
                                                                                                    • Repository
                                                                                                      • HTA-Newsletter
                                                                                                        • Annual Reports
                                                                                                        • Search
                                                                                                          Netzwerk
                                                                                                          • Eunethta
                                                                                                          • Ebm
                                                                                                          • Inahta
                                                                                                          • Dexhelpp
                                                                                                          Shareholder
                                                                                                          • Bmfg
                                                                                                          • Sv
                                                                                                          • Wgfond
                                                                                                          • Noe
                                                                                                          • Ooghfond
                                                                                                          • Ghls
                                                                                                          • Tirol
                                                                                                          • Vorarlberg
                                                                                                          • Kghfond
                                                                                                          • Ghpf
                                                                                                          • Burgef
                                                                                                          • Contact
                                                                                                            • Imprint
                                                                                                              • Privacy Notice
                                                                                                                • Newsletter
                                                                                                                  • Sitemap
                                                                                                                    © 2023 HTA Austria - Austrian Institute for Health Technology Assessment GmbH. Alle Rechte vorbehalten.
                                                                                                                    • Log in